Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

eganelisib (IPI-549)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Infinity Pharma

Drug class:

PI3Kγ inhibitor

Related drugs:

‹

›

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive : C2	bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive : C2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab + IPI-549 Sensitive : C2	bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab + IPI-549 Sensitive : C2
PD-L1 underexpression	Urothelial Cancer	PD-L1 underexpression	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
PD-L1 negative	Urothelial Cancer	PD-L1 negative	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3